Corvus Pharmaceuticals (CRVS) Scheduled to Post Quarterly Earnings on Tuesday

Corvus Pharmaceuticals (NASDAQ:CRVS) is scheduled to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.11) per share for the quarter.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.05. During the same period in the previous year, the company posted ($0.14) earnings per share. On average, analysts expect Corvus Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Corvus Pharmaceuticals Price Performance

NASDAQ CRVS traded up $0.18 during trading on Wednesday, reaching $9.41. The company’s stock had a trading volume of 56,834 shares, compared to its average volume of 338,962. The firm has a fifty day moving average of $6.08 and a 200 day moving average of $3.67. The stock has a market capitalization of $588.60 million, a PE ratio of -20.51 and a beta of 1.05. Corvus Pharmaceuticals has a one year low of $1.23 and a one year high of $9.70.

Wall Street Analyst Weigh In

CRVS has been the subject of several analyst reports. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. LADENBURG THALM/SH SH lifted their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $10.83.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.